Barclays Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $110
Portfolio Pulse from jenniferd'souza@benzinga.com
Barclays analyst Balaji Prasad has maintained an Overweight rating on Ligand Pharmaceuticals (NASDAQ:LGND) but lowered the price target from $120 to $110.
July 25, 2023 | 10:59 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays has maintained an Overweight rating on Ligand Pharmaceuticals but lowered the price target from $120 to $110.
The news is directly related to Ligand Pharmaceuticals. While the Overweight rating indicates a positive outlook, the lowering of the price target may have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100